Sign in
WithdrawnNo phase

Continuous Ambulatory Monitoring to Predict Elevated Risk of Infection in Children With Lymphoblastic Leukemia Undergoing Induction Chemotherapy (CAMPER-ALL)

Key facts

Who runs it
St. Jude Children's Research Hospital
Where
Memphis, United StatesSee the site
Trial code
Status
Withdrawn
Started
Sept 2024
Ended
Jul 2025
Type of study
Observational
Treatments tested
  • Wearable Sensors
Record updated
25 September 2024
Why it stopped
The study was activated at the onset of the COVID pandemic. At that time voluntary, non-therapeutic research was placed on hold. Now the technology has evolved and have elected to forego this protocol.

Who can take part

Age
5 years to 25 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • Between 5 and 25 years of age at time of study enrollment
  • Undergoing induction therapy for acute lymphoblastic leukemia at St. Jude
  • Expected to remain outpatient during periods of high infection risk

Who cannot take part

  • Documented allergy to components of the device (Empatica E4: elemental silver, polyurethane, or polycarbonate; TempTraq: latex-free adhesive)
  • Any condition that would, in the opinion of the investigator, place the subject at an unacceptable risk of injury or render the subject unable to meet the requirements of the protocol
  • Current fever or sepsis at time of enrollment

Where in United States

  • St. Jude Children's Research HospitalMemphis, United States

About the trial

What the trial wants to find out

Acute lymphoblastic leukemia (ALL) is the most common cancer of childhood and long-term survival has risen to above 90%, but 1-4% of treated patients die from infections. Early detection and treatment of infection can improve these outcomes by preventing increased severity and death. This study aims to determine whether continuous analysis of information from wearable devices (Like a watch and sticky patch) that measure temperature, pulse rate, oxygen level, and other similar information can predict infection before it is apparent to the patient or caregiver. About 65 patients will be enrolled and will wear these devices for 10 days; during that time the information will be recorded, but not available. After completion, information collected immediately before infection will be compared to other times to identify features that predict infections.

The group in the trial

  • Participants

    Participants will be enrolled during induction therapy for ALL, before the first high-risk period of treatment, and will contribute data for two 5-day periods of continuous monitoring.

    Treatment: Wearable Sensors

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
25 September 2024